Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John M Asara, Ph.D.

Profile Picture

Brandeis University, Waltham, MABA05/1995Chemistry
Michigan State University, East Lansing, MIPh.D.12/1999Analytical Chemistry
Harvard University, Cambridge, MAPostDoc04/2002Proteomics
10 out of 100 Top Scientific Discoveries
Plenary Lecturer
Young Investigator Award
Faculty of 1000, Biology, Signal Transduction
Outstanding Poster Award
Shared Instrumentation Grant Award
Capital Equipment Award
Academic Partnership Award

Research activities in the Asara lab focusses on the development of merging tri-omics (proteomics, metabolomics and lipidomics) data. We apply these methods for a personalized medicine approach by analyzing cancer cells and tumor samples in order help make appropriate therapeutic decisions with "smart" drugs. This is accomplished by understanding how cancer cells are signaling for growth and proliferation and how signaling talks to metabolic processes in order to develop mass spec quantitative assays. We are developing hypothesis directed proteomics and gloabl metabolomics and lipidomics strategies to understand the fundamental drivers of disease in cancers such as multiple myeloma, lung cancer and prostate cancer by performing protein-protein interaction studies, immunoprecipitation (IP)-tandem mass spectrometry (MS/MS), quantitative phosphoproteomics, metabolic and lipidomic profiling as well as metabolic flux analyses. Taken together, this information is vital in selecting the appropriate use of newly developed drugs. In addition to our internal research, we are involved in many collaborative projects that are coordinated through our state-of-the-art high resolution mass spectrometry technologies and services through our mass spectrometry facility.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. S10OD010612 (ASARA, JOHN M) May 1, 2012 - Apr 30, 2013
    High Resolution Mass Spectrometry System
    Role: Principal Investigator
  2. P01CA120964 (KWIATKOWSKI, DAVID J.) Apr 1, 2006 - Jul 31, 2023
    Molecular Pathogenesis of the Hamartoma Syndromes
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zhao H, Teng D, Yang L, Xu X, Chen J, Jiang T, Feng AY, Zhang Y, Frederick DT, Gu L, Cai L, Asara JM, Pasca di Magliano M, Boland GM, Flaherty KT, Swanson KD, Liu D, Rabinowitz JD, Zheng B. Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth. Nat Metab. 2022 Nov 14. PMID: 36376563.
    Citations:    Fields:    
  2. Zhou RW, Xu J, Martin TC, Zachem AL, He J, Ozturk S, Demircioglu D, Bansal A, Trotta AP, Giotti B, Gryder B, Shen Y, Wu X, Carcamo S, Bosch K, Hopkins B, Tsankov A, Steinhagen R, Jones DR, Asara J, Chipuk JE, Brody R, Itzkowitz S, Chio IIC, Hasson D, Bernstein E, Parsons RE. A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nat Commun. 2022 Oct 17; 13(1):6041. PMID: 36253360; PMCID: PMC9576746.
    Citations:    Fields:    Translation:AnimalsCells
  3. Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM. PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. Cell Rep. 2022 10 11; 41(2):111462. PMID: 36223740.
    Citations:    Fields:    Translation:Cells
  4. Zarei M, Hajihassani O, Hue JJ, Graor HJ, Loftus AW, Rathore M, Vaziri-Gohar A, Asara JM, Winter JM, Rothermel LD. Wild-type IDH1 inhibition enhances chemotherapy